TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

计划入组 4 人 · 首次发布于 2016 年 1 月 8 日

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

计划入组 53 人 · 首次发布于 2015 年 5 月 1 日

TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

计划入组 13 人 · 首次发布于 2011 年 4 月 13 日

INH-50

toll-like receptor modulator (Opsona/Pfizer)

Toll-like receptor agonist liposome(CSPS)

Hut 8 Corp

Canada

Arvinas Estrogen Receptor, Inc.

United States

Arvinas Androgen Receptor, Inc.

United States

Noxopharm's Sofra Platform Shows 200-Fold Immune Activation Boost in Cancer Research

FDA Grants Fast Track Designation to GSK's Bepirovirsen for Chronic Hepatitis B Treatment

Eikon Therapeutics to Present Phase 2 Data on Novel TLR7/8 Co-Agonist EIK1001 for Advanced NSCLC at ESMO 2025